Fall 2020 Schedule
Topics Related to COVID-19
- September 17: Seroprevalence Studies
- Gelman, A. and Carpenter, B. (2020), Bayesian analysis of tests with unknown specificity and sensitivity. J. R. Stat. Soc. C. doi:10.1111/rssc.12435
- October 15: Meta-Analysis and Evidence in a Pandemic
- Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA. 2020;324(13):1292–1295. doi:10.1001/jama.2020.16747
- The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023
- Optional additional reading:
- The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. New England Journal of Medicine. DOI: 10.1056/NEJMoa2021436
- Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307–1316. doi:10.1001/jama.2020.17021
- Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048–1057. doi:10.1001/jama.2020.16349
- Dequin P, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(13):1298–1306. doi:10.1001/jama.2020.16761
- November 19: Excess Deaths
- Weinberger DM, Chen J, Cohen T, et al. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. JAMA Intern Med. 2020;180(10):1336–1344. doi:10.1001/jamainternmed.2020.3391